The presence of distant metastases is a common finding on diagnosis of pancreatic cancer; however, the mechanisms underlying the dissemination of this tumor type remain poorly understood. Loss of the p53 tumor suppressor protein has been associated with tumor progression and metastasis in several tumor types including pancreatic ductal adenocarcinoma. Here, we describe the generation of a progressive and metastatic pancreatic cancer mouse model after the somatic and sporadic delivery of avian retroviruses encoding the mouse polyoma virus middle T antigen to elastase-tv-a transgenic mice with a pancreas-specific deletion of the Trp53 tumor suppressor locus. In this model, the tumors metastasize most frequently to the liver, consistent with human pancreatic carcinomas. Analysis of metastatic lesions demonstrated that concomitant loss of the Ink4a/Arf locus was not required for metastasis; however, pancreas-specific deletion of a single Ink4a/Arf allele cooperated with Trp53 deletion in a haploinsufficient manner to accelerate tumor development. Thus, our findings illustrate the potential role of p53 loss of function in pancreatic tumor progression, demonstrate the feasibility of modeling pancreatic cancer metastasis after somatic and sporadic oncogene activation, and indicate that our model may provide a useful experimental system for investigation of the molecular mechanisms underlying pancreatic cancer progression and metastasis. Pancreatic cancer is the fourth-leading cause of cancerrelated mortalities in the United States, with ϳ32,000 deaths annually.1 The median survival after diagnosis is 6 months, and the 5-year survival rate is only 5%. These statistics reflect the advanced stage at which most pancreatic tumors are identified, exemplified by extra-pancreatic invasion and metastasis to the liver and peritoneum, and the resistance of pancreatic cancers to conventional chemotherapeutic intervention. 2,3 Thus, understanding the factors that contribute to pancreatic tumor progression and metastasis is important in combating this disease.Mouse models are attractive experimental systems for exploring the genesis and behavior of human malignancies, and as a result, several mouse models for pancreatic cancer have been generated using transgenic approaches.2,4,5 These models, although valuable, were restricted in several respects including the expression of the oncogene throughout pancreatic development. Indeed, in some of the published models mice die shortly after birth, or perinatally, with architecturally abnormal pancreata. 6 Further, because all cells of a particular lineage within the pancreas express the transgene, tumors arise in an environment of aberrant intercellular signaling, unlike the scenario of sporadic tumor development in humans, in which tumor cells are surrounded by genetically normal cells.To address these issues, we recently generated a mouse model for pancreatic cancer using the RCAS-TVA gene delivery system. 7 This system allows the sporadic postnatal delivery of oncogene-bearing avian ret...